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Abstract Lymphocytes from the peripheral blood of
patients with prostate cancer—the most frequent (non-
cutaneous) tumor in men—display epigenetic aberrations
(altered modes of allelic replication) characteristic of the
malignant phenotype. The present study aims to determine
whether replication aberrations add certainty to the suspi-
cion of prostate cancer provided by the prostate-specific
antigen (PSA) blood test. The allelic replication mode
(whether synchronous or asynchronous) was exemplified
for RB1 and AML1. These two genes normally exhibit a
synchronous mode of allelic replication. Fluorescence in
situ hybridization (FISH) replication assay was used for
replication analyses. The FISH assays were applied to
PHA-stimulated lymphocytes, established from peripheral
blood samples of 35 men referred to biopsy due to
suspected prostate cancer. Following biopsy 13 out of these
35 men were found positive for prostate malignancy. The
FISH assay—showing asynchronous or synchronous RB1
and AML1 replication—was able to predict, respectively,
the results of all biopsy-positive men and in 18 out of the
22 biopsy-negative ones. Thesemeasurements, distinguishing
biopsy-positive from biopsy-negative men, were highly
significant(P<10
−8; 100% sensitivity and 81.8% specificity).
Yet, distinguishing between the two groups of men based on
the PSA measurements was nonsignificant (P>0.70). The
FISH replication assay applied to peripheral blood lympho-
cytes of 35 men referred for biopsy significantly predicted
the outcome of the pathological examination, more precisely
than the serum PSA test. As such, the epigenetic alteration
offers a potential noninvasive blood marker, complementary
to the PSA, for a preliminary prostate cancer diagnosis.
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Introduction
Prostate cancer is the second leading cause of cancer death
in American men, following lung cancer (Jemal et al.
2008). According to the most recent data of the American
Cancer Society, about one man in six will be diagnosed with
prostate cancer during his lifetime and about 1 man in 35 will
dieofprostatecancer,whichaccountsforabout10%ofcancer-
related deaths in men (Jemal et al. 2008). Yet, more than two
million men in the United States who had been diagnosed
with prostate cancer at some point in their life are still alive
today. This may be attributed partly to early detection
achieved by the prostate-specific antigen (PSA) blood test
(Hankey et al. 1999). When the PSA test was introduced [at
the beginning of the “PSA Era,” reviewed in Stamey et al.
(2004)], serum levels bellow to 4.0 ng/mL were considered
normal, while higher values were considered abnormal and
called for performing an invasive procedure, i.e., tissue
biopsy, which is uncomfortable, painful, and costly (Carter
2000; Catalona et al. 2000). Unfortunately, the PSA test has
certain limitations, as it appears that 10–15% of men with
PSAvalues below 4.0 ng/mL have malignant prostate tumors,
and two out of three men with elevated (>4.0 ng/mL) PSA
levels are free from prostate cancer but suffer from benign
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DOI 10.1007/s13148-011-0029-3prostate hyperplasia (BPH), prostatitis, or other nonmalignant
prostate irregularities (Stamey et al. 2004). Accordingly,
during the last few years, the PSA cutoff values are under
debate (Carter 2000;C a t a l o n ae ta l .2000; Smith et al. 2008).
The latest recommendations of the ACS give the cutoff value
of 2.5 ng/mL (Jemal et al. 2008) ,l e a d i n gt oa ni n c r e a s ei nt h e
number of biopsies in patients with elevated PSA, resulting
from nonmalignant causes (Applewhite et al. 2002;E i c h l e re t
al. 2006). In light of the low specificity of PSA, urologists
and oncologists would clearly welcome novel blood markers
that would differentiate biopsy-positive from biopsy-negative
cases with higher specificity (Stamey et al. 2004).
Recently, it was reported that DNA replication-timing
analyses applied to peripheral blood lymphocytes of cancer
patients differentiate between prostate cancer subjects and
BPH individuals. In brief, allelic counterparts of various
“cancer genes” such as RB1, AML1, TP53,a n dC-MYC,
which normally replicate synchronously in phytohemagglu-
tinin (PHA)-stimulated lymphocytes, will replicate highly
asynchronously in prostate cancer patients (Dotan et al.
2004, 2008).
Asynchronous replication of allelic counterparts is a
characteristic epigenetic marker of monoallelically expressed
genes (Goldmit and Bergman 2004). A simple method for
evaluating the temporal order of allelic replication utilizes
the fluorescent in situ hybridization (FISH) assay (Boggs and
Chinault 1997; Dotan et al. 2008). Of major importance for
this work is the fact that the temporal order (synchronous or
asynchronous) of replication of two allelic counterparts is
preserved even in cells in which these alleles are not
expressed. Therefore, the order of allelic replication can be
used as a marker of whether the alleles of a particular gene
are epigenetically marked in a similar or a different mode
(Ensminger and Chess 2004).
The abnormal replication pattern of various “cancergenes”
observedinbloodcellsofprostatecancerpatients(Dotanetal.
2004, 2008) appears to be non-cancer-type specific (Amiel et
al. 2000, 2001a, b;B r á se ta l .2008; Dotan et al. 2000;
Grinberg-Rashi et al. 2010; Korenstein-Ilan et al. 2002).
Whatever the mechanism giving rise to the epigenetic
replication aberrations in the blood lymphocytes, this study
will check the potential of the replication timing analyses for
predicting the biopsy results.
Material and methods
Study subjects
This study included 35 male, consenting urology patients,
above 50 years old who had a life expectancy of at least
10 years and were referred to biopsy because of suspected
prostate cancer. Digital rectal examinations (DRE) of 34
individuals (out of the 35 studied) reported negative results,
only 1 appeared positive by the test. Each patient was
evaluated for the blood level of the PSA. Histological
examinations were carried out on tissues removed from the
prostate gland by biopsy, performed according to the
sextant scheme with at least 12 cores (2 from each sextant
regiment) obtained from each patient. The outcome of the
histological test of each patient was released at the end of
the study, following completion of the FISH analyses. The
histological results indicated that 13 individuals (including
that with a positive DRE outcome) were prostate cancer
positive (designated hereinafter “CAP”), and 22 were found
to be negative for prostate cancer by the biopsy procedure
[designated hereinafter “BN” (biopsy negative)].
Cell culture
Each subject, prior to the invasive biopsy procedure, donated
5 mL of peripheral blood from which cell cultures of PHA-
stimulated lymphocytes were set up according to standard
protocol used for routine karyotype analyses (Dotan et al.
2004). Following harvesting, cells were fixed and stored in
suspension in the fixative solution (3:1 methanol to acetic
acid) at −20°C until used for FISH analysis.
Probes
We tested two loci using directly labeled commercial
probes obtained from Vysis (Abbott Laboratories, Abbott
Park, IL, USA): (1) the RB1 probe (LSI 13; 32–190001)
and (2) the AML1 probe (LSI 21; 32–190002).
In situ hybridization
We followed a standard protocol as recommended by
Abbott Laboratories, with a few minor changes. Cells were
dropped onto two well slides (Insitus Biotechnologies,
Albuquerque, NM, USA) without any pretreatment. Five
microliters of probe solution was placed on the target cell
area of the slides and covered with a round 12-mm
silianized cover-slip (Insitus Biotechnologies), which was
then sealed with rubber cement. The slides were placed into
a micro-heating system (Vysis HYBrite, Abbott Labs),
programmed for 6 min denaturation at 76°C followed by
18 h hybridization at 37°C.
Post hybridization treatment
Post hybridization washes of each probe consisted of
immersing the slides for 2 min in a solution of 0.4x saline
sodium citrate (SSC) pH 7.0 with 0.3% NP40 (Nonidet P40
deterent) at 72°C, followed by 2 min in 2x SSC with 0.1%
NP40 at room temperature in a shaking water bath. After
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containing 4,6-diamidino-2-phenylindole (3 μg/mL; Vector
Laboratories, Burlingame, CA, USA), covered with a glass
cover-slip and stored at −20°C until analyzed.
Cytogenetic evaluation
Slides were analyzed blindly using an Olympus BH2
fluorescent microscope, fitted with a triple band-pass filter
(Chroma Technology, Brattleboro, VT, USA). For each
sample, at least 200 cells exhibiting two distinct well-defined
fluorescence signals were blindly scored for each probe. The
structure of each signal, either singlet (S), representing a non-
replicated sequence, or doublet (D), disclosing a replicated
sequence, was noted. Thus, cells appeared to carry either two
asynchronous signals (SD; Fig. 1a) or synchronous signals
(SS and DD; Fig. 1b, c, respectively). For each locus, the
frequencies of SD cells, out of the total population of cells
containing two signals (total of SD, SS, and DD cells), were
noted. The frequency of SD cells was used to estimate
whether a locus replicated synchronously or asynchronously:
a low range of frequencies would indicate synchrony and a
high range of frequencies would indicate asynchrony. Our lab
experience shows that in samples of PHA-stimulated lym-
phocytes, following hybridization with a commercial probe, a
frequencybellow to 25% is regarded low, sinceit characterizes
normally biallelic loci (Dotan et al. 2008).
Statistical method
The statistical significance of the differences between two
cell populations was determined using the two-tailed
Student's t test (Microsoft Excel), with P<0.01 considered
to be statistical significant.
Ethical basis
Informed consent was obtained from each patient examined,
and the study was approved by the institutional review board.
Results
The frequencies of SD cells for RB1 and AML1 in cell
samples of all 13 patients positively diagnosed by biopsy
(CAP cases) ranged between 26.0% and 40.0% for RB1 and
26.5–37.0% for AML1. At the same time, the corresponding
values in 19 out of the 22 patients negatively diagnosed by
biopsy (BN cases) ranged between 15.7% and 23.0% for
RB1 and 13.4–26.5% for AML1. Yet, cell samples of three
BN cases displayed high SD values for both genes, similar
to those observed for the CAP patients—32.1%, 33.2%,
and 34.0% for RB1 and 31.0%, 32.2%, and 31.0% for
AML1, respectively (Fig. 2a). No statistical differences
were observed within each group between the SD values
for RB1 and those for AML1 (P>0.65 for the CAP group of
samples and P>0.80 for the BN group).
By assessing each patient's mean SD value of the RB1
and AML1 loci, all CAP samples ranged above 24% (100%
sensitivity) while only 4 out of the 22 BN samples
exhibited SD values above 24% (81.8% specificity,
Fig. 2b). The differences in SD values between the two
groups of patients were highly significant, P<10
−7 for RB1,
P<10
−8 for AML1, and P<10
−8 for the combined RB1 and
AML1 data (Fig. 3a).
It is worth mentioning that the SD values for RB1 and
AML1 found in the BN group were similar to those
observed previously [described by Korenstein-Ilan et al.
(2002)] for these loci in subjects without cancer, designated
controls (Fig. 3a).
On the other hand, in the group of 35 men studied here,
there was no significant difference (P>0.70) between the two
groups in the serum levels of PSA (Fig. 3b). The PSAvalues
of the CAP patients ranged between 2.1 and 17.6 ng/mL
(mean and standard deviation of 8.4±4.8 ng/mL) and that of
the BN subjects was 1.9–25.0 ng/mL (mean and standard
deviation of 9.1±5.7 ng/mL, Figs. 2b and 3b). In the group
of 35 men studied here, serum PSA levels above 4 ng/mL
were displayed by 10 (out of 13) CAP cases and by 21 (out
of 22) BN cases (Fig. 2b).
Fig. 1 Fluorescent signals in
PHA-stimulated lymphocytes at
interphase following one-color
FISH with the AML1 probe.
a Cell with one singlet and one
doublet (SD cell), which is an
S-phase cell in which one allele
has replicated while its partner
has still to do so; b cell with two
singlets (SS cell), in which
neither allele has replicated;
and c cell with two doublets
(DD cell), in which both alleles
have replicated
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We investigated the level of replication synchrony of the
allelic counterparts of two cancer-related genes (RB1 and
AML1): RB1—the retinoblastoma tumor-suppressor gene—
is the first known tumor suppressor gene which was the
first such gene to exhibit epigenetic rather than genetic
inactivation in a tumor suppressor gene, which was linked
to an allele-specific event [reviewed in Sakai et al. (1991)];
and AML1, which is an ETS family gene involved in the
multiple 8;21 translocations associated with leukemia
[reviewed in Zhang and Rowley (2006)]. Normally, these
two “cancer genes” exhibit a synchronous mode of allelic
replication. Yet, in peripheral blood cells of prostate cancer
patients, each displayed a loss of synchrony, a behavior
normally observed in genes subjected to allelic specific
expression (reviewed in the introduction). Here, we show
that all patients tested positively by prostate biopsy
displayed, in their lymphocytes, replication aberrations (the
change from synchronous to asynchronous modes of replica-
tion) in both studied genes (100% specificity). At the same
time, most cases in our study group (18 out of the total of 22)
that were diagnosed as prostate cancer free under biopsy
displayed normal synchronous replication of these genes,
similar to that observed previously (Korenstein-Ilan et al.
2002) for non-cancerous controls. Yet, the four biopsy-
negative cases showed asynchronous modes of replication
for both genes, similar to those observed in the biopsy-
positive cancer cases. Simply, these results point to a reduced
specificity (∼82%). However, since prostate histopathologic
Fig. 2 Distribution of blood
samples according to their SD
values (a) and SD vs. PSA
values (b). CAP–samples of
patients diagnosed cancer
positive by the prostate biopsy
examination; BN—sample of
patients diagnosed cancer-
negative by the prostate biopsy
examination. Note the consider-
able high separation, between
the two groups, attained by the
SD values, and low separation
achieved by the PSA blood
levels
Fig. 3 Mean and standard devi-
ation values of SD (a) and
PSA (b). The upper boxes
within each frame present the
level of significance (P) of the
differences between the biopsy-
cancer-positive group (CAP;
13 cases) and the biopsy-cancer-
negative (BN; 22 cases) group
for the relevant parameter. The
striped (last two) bars in frame
(a) present SD values reported
previously for RB1 (15 cases)
and for AML1 (41 cases) in
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false negative rate as high as 30% (Applewhite et al. 2002;
Eichler et al. 2006), it is logical to assume that some of these
asynchronous FISH-tested patients are in fact prostate cancer
cases missed by the histopathologic examination. This
assumption could be tested by subjecting these biopsy-
negative subjects to repeat biopsies. A reversal of some of
these pathological determinations would further strengthen
the specificity of the FISH approach. However, if
asynchronous replication cases are clearly free of prostate
cancer (false positives in our study), there is a possibility
that these patients may be suffering from some other
malignancy, as the epigenetic aberrations we measured
are also seen in the lymphocytes of patients with
miscellaneous hematological malignancies (Amiel et al.
2000, 2001a, b; Korenstein-Ilan et al. 2002;N a g l e re ta l .
2004, 2010), renal cell carcinoma (Dotan et al. 2000), and
breast cancer (Grinberg-Rashi et al. 2010).
However, even if the false positives observed by the
epigenetic assay are truly prostate cancer-free individuals,
our assay is still promising for forecasting the biopsy
results. As such, the epigenetic aberrations in peripheral
blood lymphocytes offer a potential noninvasive assay to
differentiate between patients that require biopsy to verify
the diagnosis based on elevated PSA and those that have no
need to undergo the invasive biopsy procedure. Our test is
also superior to the “liquid biopsy” examination based on
circulating tumor cells (CTCs) in the blood stream of cancer
patients. Because CTCs are extremely rare, they require
laborious and compound technologies to be captured and
isolated [reviewed in Stott et al. (2010)].
Although the mechanism giving rise to the measurable
epigenetic alterations in lymphocytes of cancer patients is still
obscure, it appears to be highly dependent on methylation
capacity (Dotan et al. 2004, 2008; Korenstein-Ilan et al.
2002;N a g l e re ta l .2004, 2010). This is in line with studies
showing that methylation capacity of cancer-critical genes
may be of use in differentiating between prostate tissues
obtained from BPH subjects and those from prostate cancer
patients (Costa et al. 2007;H a r d e ne ta l .2003).
Finally, replication timing measurements in PHA-
stimulated lymphocytes provide potential blood indicators
that would go along with PSA testing in identifying patients
who should undergo biopsy to verify their cancer status.
Such a combination could reduce the need for biopsies.
Although the replication assay was carried out on a limited
number of subjects, the obtained results clearly indicate the
need of expanding the protocol to include a much larger
group of suspected prostate cancer patients.
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